News Headlines

  1. Fujifilm Invests In VALANX Biotech To Strengthen ADC CDMO Capabilities 3/12/2026

    FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announces its investment in VALANX Biotech (Vienna, Austria; hereinafter “VALANX”), an Austrian biotechnology company with advanced manufacturing technologies for antibody-drug conjugates (ADCs), one of the key next-generation biopharmaceutical modalities.

  2. Merck Signs MoU With Cyto-Facto To Advance Cell And Gene Therapy Development And Manufacturing In APAC 3/11/2026

    Merck, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with Cyto-Facto Inc., a specialist CDMO (Contract Development and Manufacturing Organization) focused on cell and gene therapies.

  3. Chiesi And Bespak Partner To Advance Carbon Minimal Inhaler Production With UK Manufacturing Site 3/11/2026

    Chiesi Group ("Chiesi"), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, today announced an expansion of their long-standing partnership, increasing pressurized metered dose inhaler (pMDI) manufacturing capacity at Bespak’s Holmes Chapel site to support the next phase of Chiesi’s Carbon Minimal Inhaler (CMI) program.

  4. George Medicines Signs Exclusive Licensing Agreement With Ahngook Pharmaceutical To Commercialize GMRx2 In Korea 3/11/2026

    George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, has entered into an exclusive licensing and supply agreement with Ahngook Pharmaceutical Co. Ltd (“Ahngook Pharm”) (KOSDAQ: 001540), of Seoul, Korea, granting Ahngook Pharm exclusive rights to seek regulatory approval of, and to commercialize, GMRx2 in Korea.

  5. Bavarian Nordic And Serum Institute Of India Expand Strategic Partnership With Chikungunya Vaccine Manufacturing Agreement 3/11/2026

    Copenhagen, Denmark Bavarian Nordic A/S (OMX: BAVA) today announced an expansion of the strategic partnership with Serum Institute of India Pvt. Ltd. (SII) to include a contract manufacturing agreement covering a full tech transfer of the manufacturing process for the chikungunya vaccine (CHIKV VLP) from Bavarian Nordic to SII to allow for scaling of capacity to enable future supply to endemic low- and middle-income countries (LMICs).

  6. Catalent And GelMEDIX Enter Global Partnership For The Development And Clinical Manufacturing Of iPSC-Derived Cell Therapies In Ocular And Retinal Diseases 3/11/2026

    GelMEDIX Inc., a biotechnology company developing regenerative therapies to restore vision, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced a global partnership to access Catalent’s GMP-induced pluripotent stem cells (iPSC) and Catalent’s cell therapy manufacturing expertise and capabilities to support the development and clinical manufacturing of GelMEDIX’s iPSC-derived cell therapies to treat ocular and retinal diseases.

  7. Samsung Biologics Announces Collaboration With Lilly To Establish New Gateway Labs Site In Korea 3/10/2026

    Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced a collaboration agreement with Eli Lilly and Company (Lilly) to establish a Lilly Gateway Labs (LGL) site in Korea.

  8. mAbxience Selects Genedata Bioprocess To Automate End-To-End CDMO Workflows 3/10/2026

    Genedata, a Danaher company and the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that mAbxience has selected the Genedata Bioprocess® enterprise platform to structure and harmonize all bioprocess development data across its operations.

  9. Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration To Support BOT+BAL Manufacturing Needs 3/10/2026

    Agenus Inc., a leader in immuno-oncology innovation, today announced that it has triggered the first $20M contingent payment under its previously disclosed strategic collaboration with Zydus Lifesciences Ltd.

  10. Polyrizon Announces GMP Manufacturing Of Clinical Trial Material (CTM) With Eurofins CDMO AmatsiAquitaine S.A.S For Planned U.S. Clinical Study 3/10/2026

    Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced the successful production of a Good Manufacturing Practice (GMP) batch of clinical trial material (CTM) for its lead product candidate.